Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, has announced that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement, as detailed in the company press release.
Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, has announced that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement, as detailed in the company press release.
Latham & Watkins LLP represents Codexis, Inc. in the transaction with a Silicon Valley-based corporate team led by partner Patrick Pohlen with associates Alexander White and Dylan Peterson.
